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EFFECT OF A POLICY CHANGE ON USE OF 
BLOOD GLUCOSE MONITORS BY DIABETICS 
WITH MEDICARE COVERAGE
Silverman BG
Health Care Financing Administration, Baltimore, MD, USA
OBJECTIVE: To study the impact of a Medicare policy
change, effective July 1998, extending coverage for glu-
cose test equipment to all diabetics, including those not
using insulin. METHODS: Using a file of 5% of Medi-
care beneficiaries, we identified those with continuous
fee-for-service coverage from 1996-1998 and a diabetes
diagnosis on inpatient or physician claims in 1997. Mon-
itor and test strip use was determined by allowed claims
in the durable medical equipment claim files. RESULTS:
We identified 163,990 diabetic subjects (estimated preva-
lence among Medicare beneficiaries, 14%). Fourteen per-
cent of diabetics were estimated to have used glucose
monitors prior to January 1997; an additional 6.1% had
new monitor claim(s) between January 1997 and Decem-
ber 1998. From July through December 1998, mean
number of new monitor users per month was nearly tri-
ple that observed prior to July 1998. Nearly all of those
beginning monitor use between January 1997 and June
1998 had claim modifiers indicating insulin dependence,
compared to 59% of new users between July and Decem-
ber 1998. The proportion of subjects with test strip or
monitor claims in 1999 did not differ significantly be-
tween those who commenced use prior to July 1998, and
those who did so between July 1998 and December
1998; among new users of monitors, insulin users and
non-users were equally likely to have monitor or strip
claims in 1999. Insulin users had a higher number of
claims per person. CONCLUSIONS: Although extended
coverage increased new glucose monitor use in insulin us-
ers and non-users, overall use by diabetics remained rela-
tively low. New and established users were equally likely
to sustain use in 1999. As new technology becomes avail-
able for glucose monitoring, claims data offer a method
of identifying the potential target population and esti-
mating the likely impact of coverage policy changes on
utilization and costs.
Average
Bootstrapping 95%
confidence level
Total costs per patient and
year [DM] 5,539 5,184–5,894
Total costs for Germany [DM] 21 billion 19,5–22,5 billion
HbA1c 7.84 7.63–8.07
Treatment type [%]
Diet 19.4 16.7–22.1
OAD 53.0 49.6–56.4
Insulin 27.6 24.5–30.7
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THE ECONOMIC BURDEN OF TYPE 2 DIABETES 
ON THE INDIVIDUAL
Holmes J1, Bottomley J2, Gillam S3, Murphy M4
1Economists Advisory Group (EAG), London, UK; 2SmithKline 
Beecham Pharmaceuticals, Hertfordshire, UK, 3The King’s Fund, 
London, UK, 4British Diabetic Association, London, UK
OBJECTIVE: To estimate the personal expenditure and
lost earnings borne by individuals as a result of Type 2
Diabetes. METHOD: A postal questionnaire was sent to
a random sample of 750 Type 2 Diabetes patients and
their informal carers at each of 4 UK clinical centres as
part of the T2ARDIS cost of illness survey. The samples
were drawn from registers including patients receiving
only primary care as well as those receiving hospital care.
Personal expenditure data were collected from the ques-
tionnaire. Lost earnings were estimated for working age
respondents who reported that they were not working
full time because of their diabetes or because of the de-
mands of caring for someone with Type 2 Diabetes. Age
and gender specific average earnings were then applied,
adjusted downwards for national unemployment. RE-
SULTS: A total of 1578 patients (52.6%) and 500 regu-
lar informal carers responded to the survey. There was
no significant response bias amongst the patients, based
on checks of non-respondent demographics and treat-
ment regimes. The patients (n  1578) reported average
personal expenditure of £234 per year (SD 1486), but
those with an informal carer (n  500) reported higher
average expenditure at £384 per year (SD 2195). A wide
range of expenditure items was reported but the largest
single category of expenditure was private healthcare and
OTC medication. Carers themselves (n  500) reported
an average of £161 (SD 549) personal expenditure per
year. The lost earnings of patients and carers combined
were estimated at £568 (SD 3463) per patient (n  1578),
and £1441(SD 5620) per patient with a carer (n  500).
CONCLUSION: People with Type 2 Diabetes and their
informal carers incur a substantial economic burden, be-
fore consideration of the impact on their quality of life.
This burden includes significant personal expenditure,
particularly on private healthcare, and significant lost
earnings as a result of the condition.
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THE FINANCIAL EFFECTS OF INTERFACE 
AGREEMENTS FOR DIABETES MELLITUS: 
SOCIOECONOMIC RELEVANCE OF INTENSIVE 
CONTROLLED INSULIN THERAPY WITH 
INSULIN LISPRO COMPARED TO REGULAR 
HUMAN INSULIN
Kilburg A1, Clouth J2, Daniel D1, Kirchhoff D1, Rychlik R1
1Institute of Empirical Health Economics, Burscheid, Germany; 
2Lilly Deutschland GmbH, Bad Homburg, Germany
OBJECTIVES: To assess the costs of intensive controlled
therapy with insulin lispro compared to regular human
